Alpha-Cypermethrin

Alpha-Cypermethrin

SCHEMBL942530

CC1(C)C(C=C(Cl)Cl)[C@H]1C(=O)O[C@@H](C#N)c1cccc(Oc2ccccc2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 1.00
ALDH1A1 P00352 1/20 1.00
LMNA P02545 3/20 0.58
ATM Q13315 3/20 0.58
ADRA2A P08913 1/20 0.58
CNR1 P21554 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
PTGS1 P23219 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
CYP2D6 P10635 1/20 0.41
ALOX5 P09917 1/20 0.39
TSHR P16473 3/20 0.37
POLB P06746 1/20 0.37
MAPT P10636 1/20 0.37
HTT P42858 1/20 0.37
RAB9A P51151 1/20 0.37
CYP1A2 P05177 1/20 0.35
CYP2C19 P33261 1/20 0.35
AKR1C3 P42330 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Alpha-Cypermethrin SCHEMBL5074418 1.00 TDP1 (1.00) TDP1ALDH1A1LMNAATMADRA2A
Beta-Cypermethrin SCHEMBL5934059 1.00 TDP1 (1.00) TDP1ALDH1A1LMNAATMADRA2A
Alpha-Cypermethrin SCHEMBL942094 1.00 TDP1 (1.00) TDP1ALDH1A1LMNAATMADRA2A
Alpha-Cypermethrin SCHEMBL1088177 1.00 TDP1 (1.00) TDP1ALDH1A1LMNAATMADRA2A
Alpha-Cypermethrin SCHEMBL120157 1.00 TDP1 (1.00) TDP1ALDH1A1LMNAATMADRA2A
Alpha-Cypermethrin SCHEMBL4338885 1.00 TDP1 (1.00) TDP1ALDH1A1LMNAATMADRA2A
Alpha-Cypermethrin SCHEMBL1088295 1.00 TDP1 (1.00) TDP1ALDH1A1LMNAATMADRA2A
Alpha-Cypermethrin SCHEMBL1086935 1.00 TDP1 (1.00) TDP1ALDH1A1LMNAATMADRA2A
Alpha-Cypermethrin SCHEMBL11344290 1.00 TDP1 (1.00) TDP1ALDH1A1LMNAATMADRA2A
Alpha-Cypermethrin SCHEMBL1087559 1.00 TDP1 (1.00) TDP1ALDH1A1LMNAATMADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110002877-A1 PTEN Inhibitors Treat Neutropenia-Associated Pneumonia CHILDREN'S MEDICAL CENTER CORPORATION 2011-01-06 US claimed
US-10941194-B2 Methods of diagnosing and treating autism spectrum disorders THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-03-09 US disclosed
US-10117866-B2 Promoting axon regeneration in the adult CNS through control of protein translation CHILDREN'S MEDICAL CENTER CORPORATION (US) 2018-11-06 US disclosed
US-20180002410-A1 METHODS OF DIAGNOSING AND TREATING AUTISM SPECTRUM DISORDERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2018-01-04 US disclosed
US-9492408-B2 Protection from chemical-induced acute lung injury University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2016-11-15 US disclosed
US-9492408-B2 Protection from chemical-induced acute lung injury University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2016-11-15 US disclosed
US-20150119468-A1 PROTECTION FROM CHEMICAL-INDUCED ACUTE LUNG INJURY University of Pittsburgh–of the Commonwealth System of Higher Education (US) 2015-04-30 US disclosed
US-20150119468-A1 PROTECTION FROM CHEMICAL-INDUCED ACUTE LUNG INJURY University of Pittsburgh–of the Commonwealth System of Higher Education (US) 2015-04-30 US disclosed
US-20140213609-A1 PROMOTING AXON RENEGERATION IN THE ADULT CNS THROUGH CONTROL OF PROTEIN TRANSLATION CHILDREN'S MEDICAL CENTER CORPORATION (US) 2014-07-31 US disclosed
US-20110002877-A1 PTEN Inhibitors Treat Neutropenia-Associated Pneumonia CHILDREN'S MEDICAL CENTER CORPORATION 2011-01-06 US disclosed
US-20070203098-A1 Pten Inhibitors SEMAFORE PHARMACEUTICALS, INC. (US) 2007-08-30 US disclosed
US-20070203098-A1 Pten Inhibitors SEMAFORE PHARMACEUTICALS, INC. (US) 2007-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110002877-A1 PTEN Inhibitors Treat Neutropenia-Associated Pneumonia CSF3R, CSF1R, ATM TDP1 1904/4885ALDH1A1 4692/4885LMNA 3952/4885
US-20150119468-A1 PROTECTION FROM CHEMICAL-INDUCED ACUTE LUNG INJURY DUSP10, CASP10, PHF20 TDP1 1912/4885ALDH1A1 1433/4885LMNA 2543/4885
US-20070203098-A1 Pten Inhibitors PTEN, MTMR1, PTPRJ TDP1 258/4885ALDH1A1 2982/4885LMNA 2778/4885
US-20140213609-A1 PROMOTING AXON RENEGERATION IN THE ADULT CNS THROUGH CONTROL OF PROTEIN TRANSLATION GAP43, DCX, BDNF TDP1 2593/4885ALDH1A1 3981/4885LMNA 2349/4885
US-10117866-B2 Promoting axon regeneration in the adult CNS through control of protein translation GAP43, BDNF, DCX TDP1 2251/4885ALDH1A1 3775/4885LMNA 2659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.